



September 26, 2025

Company Name	EUCALIA Inc.
Representative	Hideo Misawa
Securities code	286A; Tokyo Stock Exchange Growth Section
Contact	Kazunari Ogawa, Executive Officer, Business Strategy Headquarters General Manager
Phone	+81-3-5501-2271

Notice Regarding Partnership Agreement with Medical Corporation Ikkokai

EUCALIA Inc. (Head Office: Chiyoda-ku, Tokyo, President and Representative Director: Hideo Misawa, "EUCALIA") has resolved at its Board of Directors meeting held on September 26, 2025, to conclude a partnership agreement with Medical Corporation Ikkokai (Head Office: Iruma-shi, Saitama, Chairperson: Tomoko Oda, "Ikkokai"), which operates Kobayashi Hospital (Iruma-shi, Saitama). With this addition, the number of hospitals partnering with EUCALIA has reached 31, including Kobayashi Hospital.

1. Reason for the Agreement

In Japan's super-aged society, hospitals, the core providers of community healthcare, are facing increasingly severe management challenges, such as chronic shortages of human resources. Small and medium-sized hospitals, in particular, are burdened with issues such as persistent deficits and a lack of successors, threatening the sustainability of systems that deliver essential medical services to local communities.

EUCALIA has set forth the vision of "Industrialization of Healthcare" and the mission of "Realize the Ideal form of Medical and Nursingcare through Transformation." To this end, the company provides, in addition to providing consulting services to hospitals facing difficult business environments, we also provide a broad range of services to support hospital management, from fundraising and procurement to regional collaboration, hospital reconstruction, and digital transformation and data utilization. These initiatives aim to realize a "good for all three sides (Sanpō Yoshi)" worldview: "stabilizing the management of hospitals and nursing care facilities," improving the job satisfaction and income of healthcare workers," and "improving well-being of patients and those requiring care."

Meanwhile, Ikkokai is based in Iruma-shi, Saitama Prefecture, and has long been contributing to community healthcare through the providing medical services, mainly internal medicine. The conclusion of this agreement will support the sustainable operation of Ikkokai, a

community-based medical corporation, and is positioned as an initiative that will contribute to the realization of EUCALIA's vision and mission.

2. Details of the Agreement

Through the conclusion of this agreement, EUCALIA will provide Ikkokai with its expertise in hospital management it has accumulated over many years and will provide comprehensive support for hospital operations. Specifically, the company will strengthen its management foundation by formulating business plans and establishing financial management systems, provide human resource support to enhance recruitment and retain staff, and promote medical digital transformation (DX) tailored to on-site needs thereby improving the efficiency of clinical and administrative operations. In addition, we will leverage EUCALIA's extensive nationwide network to build an optimal hospital management model that is in line with the government's Regional Healthcare Vision.

3. Overview of the Counterparty to the Agreement (Ikkokai)

(1)	Name	Medical Corporation Ikkokai
(2)	Location	2417, Miyadera, Iruma-shi, Saitama, Japan
(3)	Job Title and Name of Representative	Tomoko Oda, Chairperson
(4)	Description of Business	Kobayashi Hospital (Iruma-shi) Aoitori Home-Visit Nursing Station (Iruma-shi) Aoitori In-Home Long-Term Care Support Office (Iruma-shi) Aoitori Nursing Multifunctional Long-Term Care Small Group Home (Iruma-shi)
	Specialties	Internal Medicine, Neurology, Orthopedics, others
	Bed Capacity	Kobayashi Hospital: 93 beds
(5)	Date of Establishment	June, 1983

4. Schedule for the Agreement

(1)	Date of Resolution at the Board of Directors Meeting	September 26, 2025
(2)	Date of Conclusion of the Agreement	September 30, 2025 (scheduled)

5. Future Outlook

We anticipate that the impact of this alliance on our business results for the current fiscal year will be minimal. However, we believe it will contribute to the enhancement of

our business performance and corporate value in the medium to long term. If any matters requiring disclosure arise in the future, we will promptly announce the impact on our financial results.

End